

REMARKS

The present invention relates to certain Triazolopyrimidines, which are useful in oncology for the treatment of cancer.

Claims 1-22, 67, 70 and 73-97 are pending in the application. Restriction has been required among IV classes of the invention.

The Examiner has required a restriction under 35 USC 121 to one of the following IV groups:

- I. Claims 1-22, 67, 70 and 73-97 (part of each, drawn to the methods of claims 1 and 73 wherein the triazolopyrimidine derivatives have the following substituents:  
R<sup>1</sup> is not a ring of 7-, or 8-member, or a spiro ring;  
R<sup>2</sup> is an optionally substituted phenyl group.  
classified in classes 514, and 544, various subclasses depending on the substituents.
- II. Claims 1-22, 67, 70, and 73-97 (part of each, drawn to the methods of claims 1 and 73 wherein the triazolopyrimidine derivatives have the following substituents:  
R<sup>1</sup> is a ring of 7-, or 8-member;  
R<sup>2</sup> is an optionally substituted phenyl group.  
classified in classes 514, and 540, various subclasses depending on the substituents.
- III. Claims 1-22, 67, 70, and 73-97 (part of each, drawn to the methods of claims 1 and 73 wherein the triazolopyrimidine derivatives have the following substituents:  
R<sup>1</sup> is a spiro ring;  
R<sup>2</sup> is an optionally substituted phenyl group.  
classified in classes 514, and 540, various subclasses depending on the substituents.
- IV. Claims 1-22, 67, 70, and 73-97 (part of each, drawn to the methods of claims 1 and 73 wherein the triazolopyrimidine derivatives have the substituents not listed in the above groups. Further restriction and election will be required if this group is elected.

Applicants respectfully traverse the restriction requirement.

It is the applicants view that the definition of R<sup>2</sup> within Groups I-III, should be defined as an optionally substituted aryl group having 6, 10 or 14 carbon atoms. Further, it is the applicants view that it would be no greater burden for the Examiner to search aryl which includes phenyl. Applicants believe that the approach adopted by the Patent Office to divide cases into many divisionals actually results in a greater burden because of the necessity for each Examiner to review the entire specification of each divisional, review all of the claims, paperwork, etc.


Applicants respectfully request that the Examiner reconsider the restriction of Groups I to III and amend the definition of R<sup>2</sup> from optionally substituted phenyl to optionally substituted aryl having 6, 10 or 14 carbon atoms for each restriction Group.

Nevertheless, for the advance of prosecution the applicants provisionally elect Group I. For the convenience of the Examiner applicants elect a species of Example 133, 5-chloro-N-(2,2,2-trifluoro-1-methylethyl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine.

Applicants respectfully request that the Examiner reconsider the restriction requirement. Further, applicants reserve the right to file divisional applications for non-elected subject matter.

Favorable treatment of the application is earnestly solicited.

Respectfully submitted,



Daniel B. Moran

Reg. No. 41,204

Wyeth  
Patent Law Department  
Five Giralda Farms  
Madison, NJ 07940  
Tel. No. (845)602-2224